Smruthi Organics Ltd (540686)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Smruthi Organics' revenue was ₹29.3 Cr (+54.3% year on year, +0.7% on the previous quarter), and net profit ₹2.9 Cr (against a loss a year earlier); the operating margin was 19.8%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹29.3 | +54.3% | +0.7% |
| Operating profit | ₹5.8 | — | +53.4% |
| Net profit | ₹2.9 | from loss | +169.0% |
| EPS (₹) | 2.51 | from loss | +169.9% |
| Operating margin | 19.8% | — | — |
📢 Recent Corporate Announcements
Smruthi Organics reported a strong turnaround in Q1 FY27, posting a net profit of Rs 2.88 Cr compared to a net loss of Rs 1.10 Cr in the same quarter last year. Revenue from operations grew 55.4% YoY to Rs 29.30 Cr, driven by the API segment. A significant strategic shift was implemented with the discontinuation of the Formulations Marketing Division effective May 13, 2026, to focus exclusively on APIs and Intermediates. The quarterly profit of Rs 2.88 Cr is nearly equivalent to the company's entire TTM profit of Rs 3 Cr, indicating a sharp recovery in margins.
- Revenue from operations increased 55.4% YoY to Rs 29.30 Cr from Rs 18.85 Cr.
- Net profit turned positive at Rs 2.88 Cr vs a loss of Rs 1.10 Cr in Q1 FY26.
- API segment revenue grew 54.8% YoY to Rs 29.32 Cr, now the sole operating segment.
- Earnings Per Share (EPS) improved to Rs 2.51 from a negative Rs 0.96 YoY.
- Formulations division discontinued on May 13, 2026, to streamline operations.
Smruthi Organics reported a significant turnaround in Q1 FY27, posting a net profit of ₹2.88 Cr compared to a loss of ₹1.10 Cr in the same quarter last year. Revenue from operations grew 55.4% YoY to ₹29.30 Cr, primarily driven by the API segment. The company has strategically discontinued its loss-making Formulations Marketing Division as of May 14, 2026, to focus exclusively on Bulk Drugs and Intermediates. Notably, this single quarter's profit (₹2.88 Cr) is nearly equal to the company's entire TTM PAT of ₹3 Cr.
- Net Profit turned positive at ₹2.88 Cr in Q1 FY27 vs a loss of ₹1.10 Cr in Q1 FY26
- Revenue from operations increased 55.4% YoY to ₹29.30 Cr from ₹18.85 Cr
- API segment revenue grew to ₹29.32 Cr, representing the company's sole operating segment post-restructuring
- Basic EPS improved significantly to ₹2.51 from -₹0.96 in the year-ago period
- Formulations division discontinued effective May 14, 2026, to streamline operations and focus on core API strengths
Smruthi Organics has scheduled a board meeting on August 10, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. The company, with a market cap of ‡134 Cr, reported a TTM revenue of ‡102 Cr and a PAT of ‡3 Cr. Investors will be looking for recovery signs as the company aims for a ‡150 Cr revenue target by diversifying its product portfolio. The trading window has been closed since July 1, 2026, in anticipation of these results.
- Board meeting scheduled for August 10, 2026, to approve Q1 FY27 results
- Trading window closed from July 1, 2026, until 48 hours post-announcement
- Company reported TTM revenue of ‡102 Cr as of March 2026
- Targeting a revenue increase to over ‡150 Cr (approx. 19% growth from FY25)
- Promoter holding remains stable at 64.73% as of June 2026
Smruthi Organics has scheduled its 37th Annual General Meeting for August 10, 2026, to ratify a dividend of ₹1.50 per share (15% on face value). A key agenda item is the redesignation of Ms. Smruthi Eaga as a Whole-time Director with a proposed annual remuneration of ₹84 lakhs, a ~35% increase from her previous pay of ₹62.22 lakhs. The company noted that FY26 profitability was pressured by geopolitical uncertainties and lower sales revenue. To counter this, management is focusing on backward integration and cost optimization at its Hyderabad R&D facility.
- Dividend of ₹1.50 per share (15%) proposed for 1,14,46,290 equity shares.
- Ms. Smruthi Eaga's annual remuneration to increase from ₹62.22 lakhs to ₹84 lakhs.
- Record date for dividend eligibility set for July 31, 2026.
- AGM to be held via Video Conference on August 10, 2026, at 02:30 p.m.
- Company is implementing backward integration to reduce dependence on external raw materials.
Smruthi Organics has released its FY2025-26 Annual Report, proposing a dividend of ₹1.50 per share (15%) with a record date of July 31, 2026. A significant strategic shift was disclosed: the company will undergo a phased wind-down of its Finished Dosage Formulations Division to focus on its core business. Ms. Smruthi Eaga is being elevated to Whole-time Director with a proposed annual salary of ₹84 lakhs. While the formulations exit is a non-adjusting event for FY26, the costs and operational impact will be reflected in FY27 results.
- Proposed dividend of ₹1.50 per share (15%) on 1,14,46,290 equity shares for FY26.
- Strategic decision to discontinue the Finished Dosage Formulations Division to focus on core operations.
- Appointment of Ms. Smruthi Eaga as Whole-time Director for 3 years with a salary of ₹84 lakhs per annum.
- 37th Annual General Meeting (AGM) scheduled for August 10, 2026, via video conferencing.
- Record date for dividend eligibility set as July 31, 2026.
Financial Performance
Revenue Growth by Segment
Revenue from operations declined by 1.28% YoY, from INR 127.64 Cr in FY24 to INR 126.01 Cr in FY25. The API segment contributes over 80% of total revenue, while intermediates account for the remaining portion. Subdued performance was noted in Q1FY26 with a sharp decline in revenue and operating losses.
Geographic Revenue Split
The company caters to the Indian domestic market and Rest of the World (ROW) markets. Specific percentage splits per region are not disclosed, but the company is actively seeking to increase its presence in regulated markets to improve margins.
Profitability Margins
PAT margins remained moderate at 2.81% in FY24 (consistent with 2.93% in FY23) but significantly declined to 1.51% in 9MFY25. This compression was driven by an 82.6% increase in finance costs and competitive pressure from Chinese imports affecting sales realizations.
EBITDA Margin
PBILDT margin improved from 6.95% in FY23 to 9.37% in FY24 due to lower raw material costs. However, margins moderated to 8.55% in 9MFY25 (compared to 8.97% in 9MFY24) due to a dip in sales realization and increased competition.
Capital Expenditure
The company maintains a comfortable capital structure with no major debt-funded capital expenditure (capex) planned for the near-to-medium term. Total non-current assets stood at INR 71.63 Cr as of March 31, 2025.
Credit Rating & Borrowing
Ratings were downgraded in August 2025 to 'CARE BBB-; Stable' (Long-term) and 'CARE A3' (Short-term) from 'CARE BBB; Negative'. The downgrade reflects sustained pressure on profitability and a sharp revenue decline in Q1FY26. Finance costs rose to INR 1.83 Cr in FY25 from INR 1.00 Cr in FY24.
Operational Drivers
Raw Materials
Key raw materials include chemical compounds for API synthesis, representing the major cost driver. Specific chemical names are not listed, but they are categorized as volatile commodities sourced both domestically and internationally.
Import Sources
Raw materials are procured from both domestic Indian markets and international imports, with significant exposure to Chinese imports which create pricing pressure on finished API products.
Capacity Expansion
Current installed capacity is not specified in metric units; however, the company operates accredited manufacturing facilities. Future growth is contingent on improving the scale of operations beyond the current INR 126 Cr revenue base.
Raw Material Costs
Raw material costs are the primary expense; PBILDT margins improved to 9.37% in FY24 specifically due to a temporary softening in raw material prices, highlighting a high sensitivity to input cost fluctuations.
Manufacturing Efficiency
Depreciation and Amortization stood at INR 5.50 Cr in FY25, slightly down from INR 5.65 Cr in FY24, suggesting stable asset utilization.
Strategic Growth
Expected Growth Rate
19%
Growth Strategy
The company aims to reach a Total Operating Income (TOI) of over INR 150 Cr (a ~19% increase from FY25 levels) by diversifying its product portfolio into new therapeutic categories, reducing dependence on its top two products, and expanding geographically into regulated markets which typically offer higher realizations.
Products & Services
Active Pharmaceutical Ingredients (APIs) and intermediates. Key products include Metformin (Anti-Diabetic) and Diloxanide Furoate (Anti-Infective).
Brand Portfolio
Smruthi Organics Limited (SOL).
New Products/Services
The company is focusing on expanding its portfolio in Anti-Diabetic, Anti-Hypertension, and Anti-Infective categories to reduce concentration risk.
Market Expansion
Targeting expansion into regulated markets to diversify from current Indian domestic and ROW (Rest of World) markets.
External Factors
Industry Trends
The API industry is seeing a shift toward 'China Plus One' strategies, but SOL currently faces headwinds from Chinese dumping and price volatility. Future growth depends on successfully transitioning to regulated market standards.
Competitive Landscape
Faces intense competition from large-scale Chinese manufacturers and other domestic API players in the generic segments of Metformin and Diloxanide Furoate.
Competitive Moat
The company's moat is based on the extensive experience of its promoters (Eaga Purushotham and Eaga Swapnil) and its accredited manufacturing facilities, though this is currently weakened by high product concentration.
Macro Economic Sensitivity
Highly sensitive to global pharmaceutical supply chain shifts and trade relations with China, as Chinese imports directly affect both input costs and competitive pricing.
Consumer Behavior
Demand for Anti-Diabetic and Anti-Hypertension medication remains structurally strong due to increasing global prevalence of lifestyle diseases.
Geopolitical Risks
Trade barriers or supply disruptions from China could impact raw material availability, as the company relies on imports for key inputs.
Regulatory & Governance
Industry Regulations
Operations are subject to stringent pharmaceutical manufacturing standards and accreditation. Exposure to regulatory risk is noted as a key rating temperamental factor, particularly for exports to regulated markets.
Taxation Policy Impact
The company's current tax liability was INR 80.53 Lakhs in FY24, which was fully settled/adjusted in FY25. Deferred tax liabilities stood at INR 87.57 Lakhs as of March 31, 2025.
Legal Contingencies
The company has pending litigations disclosed in Note 40 and 46(p) of the financial statements. Specific INR values for these contingencies were not provided in the summary documents.
Risk Analysis
Key Uncertainties
The primary uncertainty is the ability to sustain margins amidst volatile raw material prices and the risk of further revenue contraction as seen in Q1FY26.
Geographic Concentration Risk
While catering to ROW, the company lacks significant revenue from highly regulated markets (USA/EU), which limits its margin potential.
Third Party Dependencies
High dependency on a limited supplier base for key starting materials, particularly those sourced from China.
Technology Obsolescence Risk
The company must continuously upgrade its facilities to meet evolving international regulatory standards for API manufacturing.
Credit & Counterparty Risk
Trade receivables stood at INR 8.54 Cr in FY25. High customer concentration (70% from top 10) increases counterparty risk if a major client faces financial distress.
